Introduction {#sec1}
============

In 2018, global cancer statistics estimated that liver malignancy was the fifth most frequent type of cancer incidence among men and the eleven most frequent type among women, about 596,574 and 244,506 new cases diagnosed worldwide, respectively \[[@B1]\]. However, the fatality was the third most frequent type \[[@B1]\]. The etiology of liver cancer (LC) was not well-established. Hepatocellular carcinoma (HCC) is one of the most important primary LC, which comprised almost 80% of LC cases. Some major susceptibility factors (e.g. aflatoxin-contaminated food, superabundant drinking, tobacco consumption, chronic virus infection, higher body mass index and Type 2 diabetes) \[[@B2]\] may contribute to the development of HCC. Additionally, hereditary factor has also been suggested to affect the susceptibility for the occurrence of HCC.

*Methylenetetrahydrofolate reductase* (*MTHFR*) locates in 1p36.3, which maps from 11785723 to 11806103 (GRCh38; April, 2018). MTHFR, a key enzyme, plays a vital effect in folate metabolism by the role of catalyzing the 5,10-methylenetetrahydrofolate (5,10-methylene-THF) to 5-methyltetrahydrofolate (5-methylene-THF) irreversibly. In the conversion of homocysteine to methionine, 5-methylene-THF is a primary methyl donor \[[@B7]\]. *MTHFR* rs1801133 (C677T), a non-synonymous variant (Ala\>Val), has been suggested to influence the activity of MTHFR enzyme \[[@B8]\]. The correlation of *MTHFR* rs1801133 polymorphism with malignancy has been extensively explored. This single-nucleotide polymorphism (SNP) was suggested to be associated with thyroid cancer \[[@B9]\], colorectal cancer \[[@B10],[@B11]\], breast cancer \[[@B12]\], esophagogastric junction adenocarcinoma \[[@B13]\], non-small cell lung cancer \[[@B14]\], acute lymphoblastic leukemia \[[@B15],[@B16]\], gastric cancer \[[@B17]\], renal cell carcinoma \[[@B18]\] and esophageal carcinoma \[[@B19]\], among others.

Recently, many case--control studies have been carried out to determine the relationship of *MTHFR* rs1801133 polymorphism with the development of HCC \[[@B19]\]. However, the observations were controversial. Several meta-analyses also got conflicting results. To shed light on this issue, we conducted an extensive pooled-analysis to determine the role of *MTHFR* rs1801133 polymorphism on the development of HCC.

Materials and methods {#sec2}
=====================

Study searching {#sec2-1}
---------------

Publications were obtained by searching the PubMed and EMBASE databases before October 19, 2019. The following strategy was used: (Methylenetetrahyfrofolate reductase OR MTHFR OR rs1801133) AND (SNP OR polymorphism) AND (cancer OR carcinoma) and (hepatocellular OR liver). The references in reviews and meta-analyses were also retrieved to get data. In this pooled-analysis, there was no language limited.

Inclusion criteria {#sec2-2}
------------------

In our meta-analysis, the eligible criteria of the included publications were: (1) designed as a case--control study; (2) focusing on the relationship of the *MTHFR* rs1801133 polymorphism with HCC risk; (3) genotype data could be extracted and (4) publications were compatible with Hardy--Weinberg equilibrium (HWE) in controls.

Exclusion criteria {#sec2-3}
------------------

The criteria for exclusion were as following: (1) publications incompatible with HWE; (2) overlapping data; (3) not case--control study design and (4) only focusing on the relationship of *MTHFR* rs1801133 polymorphism with HCC survival.

Data extraction {#sec2-4}
---------------

The authors (S. Zhang and J. Jiang) extracted the following data: the surname of first author, publication year, populations studied, country where the investigation was carried out, ratio of sex, age, drinking, positive (%) of hepatitis B surface antigen (HBsAg), genotyping method, the number of participants and *MTHFR* rs1801133 genotype. If there was conflicting assessment, another reviewer (W. Tang) was invited. During this process, they made a vote to obtain the final decision.

Statistical methods {#sec2-5}
-------------------

In the present study, the odds ratios (ORs) combined with 95% confidence intervals (CIs) were harnessed to compare the difference between HCC group and controls. *P* value (\<0.05) was considered statistically significant. The present meta-analysis determined the correlation in four genetic models \[e.g. dominant model (TT/CT vs. CC), homozygote model (TT vs. CC), allele model (T vs. C) and recessive model (TT vs. CC/CT)\]. Using *I^2^* metric and Q statistic, the heterogeneity among the eligible case--control studies was evaluated. If *P* \< 0.10 or *I*^2^ \> 50%, we defined that there was significant heterogeneity. Thus, the random-effect model was used \[[@B30],[@B31]\]. Otherwise, there was no heterogeneity detected. A fixed-effect model was used to combine the data \[[@B32]\]. The Egger test and Begg's test were used to assess the bias of publication. If *P* \< 0.10, we defined that there was a significant publication bias. By omitting a study one by one and analyzing the remainders, sensitivity analysis was performed to assess the stability of our findings. The distribution of the *MTHFR* rs1801133 genotype was used to calculate the *P* value of HWE by using an online software (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) in controls \[[@B33]\]. STATA 12.0 software (Stata Corp., College Station, Texas) was used to conduct the analysis. In this study, *P* value was two sided.

Quality assessment of meta-analysis {#sec2-6}
-----------------------------------

Two authors (S.Z. and J.J.) independently extracted the data and calculated the quality score of the included case--control studies. The detailed scores were determined by a quality assessment criteria, which were presented in previous studies \[[@B36],[@B37]\]. If the scores were more than 6.0, the investigation had an acceptable quality \[[@B38]\].

Results {#sec3}
=======

Eligible studies {#sec3-1}
----------------

A total of 11 publications were eligible ([Figure 1](#F1){ref-type="fig"}). Four articles involved several different subgroups, so we considered them as independent investigations. After a screening, 19 independent case--control studies were included. In addition, five publications were excluded for incompatible with HWE \[[@B29],[@B39],[@B40]\]. Finally, 6,102 HCC cases and 6,526 controls were recruited to examine the relationship of *MTHFR* rs1801133 polymorphism with HCC risk ([Table 1](#T1){ref-type="table"}). The publication year covered from 2004 to 2019. These investigations were performed in different populations: three were conducted in mixed populations \[[@B28],[@B29]\], four were carried out in Caucasians \[[@B26],[@B27]\], and twelve involved Asians \[[@B19]\]. The *MTHFR* rs1801133 genotypes are summarized in [Table 2](#T2){ref-type="table"}.

![Flow diagram of this meta-analysis](bsr-40-bsr20194229-g1){#F1}

###### Characteristics of the studies in meta-analysis

  Study     Year   Sample size   Country   Ethnicity   Sex, male (%); Case/Control   Age (years); Case/Control   Drinkinge (%); Case/Control   HBsAg, positive (%); Case/Control   Genotype method   Source of control   Type of control
  --------- ------ ------------- --------- ----------- ----------------------------- --------------------------- ----------------------------- ----------------------------------- ----------------- ------------------- ------------------------------------
  Cui       2012   356/641       China     Asian       83.1/43.5                     56.6/58.7                   44.1/30.3                     77.5/8.6                            Real-time PCR     PB                  Normal or healthy control
  Fabris    2009   65/147        Italy     Caucasian   NA/NA                         NA/NA                       NA                            26.2/10.9                           PCR-RFLP          HB                  Hepatitis or virus related control
  Fabris    2009   65/236        Italy     Caucasian   NA/69.5                       NA/48                       NA                            NA/NA                               PCR-RFLP          HB                  NA
  Jiao      2017   726/549       China     Asian       72.7/54.6                     56.5/41.5                   24.5/NA                       89.1/0.0                            TaqMan            HB                  Normal or healthy control
  Jiao      2017   726/558       China     Asian       72.7/53.6                     56.5/33.7                   24.5/NA                       89.1/0.0                            TaqMan            HB                  Normal or healthy control
  Jiao      2017   726/81        China     Asian       72.7/61.7                     56.5/34.4                   24.5/NA                       89.1/100                            TaqMan            HB                  Hepatitis or virus related control
  Jiao      2017   726/442       China     Asian       72.7/66.5                     56.5/39.6                   24.5/13.6                     89.1/100                            TaqMan            HB                  Hepatitis or virus related control
  Jiao      2017   726/704       China     Asian       72.7/64.9                     56.5/53.7                   24.5/23.6                     89.1/88.7                           TaqMan            HB                  Hepatitis or virus related control
  Kwak      2008   96/201        Korea     Asian       NA                            57.6/53.6                   NA                            NA                                  PCR-RFLP          HB                  Normal or healthy control
  Peres     2016   71/356        Brazil    Mixed       73.2/73.3                     NA                          62.0/46.0                     NA                                  PCR-RFLP          HB                  Normal or healthy control
  Peres     2016   71/116        Brazil    Mixed       73.2/74.1                     NA                          62.0/53.4                     NA                                  PCR-RFLP          HB                  Hepatitis or virus related control
  Saffroy   2004   72/122        France    Caucasian   84.7/85.2                     55/50                       NA                            NA                                  PCR-RFLP          HB                  Hepatitis or virus related control
  Saffroy   2004   27/80         France    Caucasian   74.1/86.3                     54/54                       NA                            NA                                  PCR-RFLP          HB                  Normal or healthy control
  Saffroy   2004   49/30         France    Caucasian   85.7/66.7                     56/52                       NA                            NA                                  PCR-RFLP          HB                  Hepatitis or virus related control
  Xu        2014   205/200       China     Asian       NA                            52.0/61.0                   NA                            NA                                  PCR               NA                  NA
  Yuan      2007   118/209       USA       Mixed       68.6/61.2                     NA                          71.2/68.4                     28.0/11.5                           TaqMan            PB                  Normal or healthy control
  Zhu       2006   508/543       China     Asian       85.8/48.8                     50/45                       39.8/17.9                     72.8/17.9                           PCR-RFLP          HB                  Normal or healthy control
  Chang     2014   204/415       China     Asian       77.9/69.2                     53.9/57.7                   41.7/35.7                     64.7/24.6                           PCR-RFLP          PB                  Normal or healthy control
  Zhang     2019   584/923       China     Asian       89.9/90.5                     53.2/53.7                   29.1/16.0                     70.6/9.2                            SNPscan           HB                  Normal or healthy control

PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism

PCR: polymerase chain reaction

SNP: single-nucleotide polymorphism

HP: hospital-based

PB: population-based

NA: not available

###### Distribution of *MTHFR* rs1801133 C\>T polymorphism genotype and allele

  Study     Year   Case TT   Case CT   Casde CC     Control TT   Control TC   Control CC    Case T   Case C   Control T   Control C   HWE   Quality assessment
  --------- ------ --------- --------- ------------ ------------ ------------ ------------- -------- -------- ----------- ----------- ----- --------------------
  Cui       2012   125       179       52           195          325          121           429      283      715         567         Yes   7.0
  Fabris    2009   13        --        CC/CT = 52   23           --           CC/CT = 124   --       --       --          --          Yes   6.5
  Fabris    2009   13        --        CC/CT = 52   54           113          69            --       --       --          --          Yes   6.5
  Jiao      2017   188       370       168          176          263          110           746      706      615         483         Yes   7.5
  Jiao      2017   188       370       168          169          268          121           746      706      606         510         Yes   7.5
  Jiao      2017   188       370       168          29           35           17            746      706      93          69          Yes   6.5
  Jiao      2017   188       370       168          120          222          100           746      706      462         422         Yes   7.5
  Jiao      2017   188       370       168          215          338          151           746      706      768         640         Yes   7.5
  Kwak      2008   18        46        32           31           106          64            82       110      168         234         Yes   6.5
  Peres     2016   7         36        28           33           174          149           50       92       240         472         Yes   7.0
  Peres     2016   7         36        28           13           55           48            50       92       81          151         Yes   6.0
  Saffroy   2004   5         24        43           10           60           52            34       110      80          164         Yes   6.5
  Saffroy   2004   2         16        9            13           37           30            20       34       63          97          Yes   6.5
  Saffroy   2004   5         29        15           3            17           10            39       59       23          37          Yes   6.5
  Xu        2014   50        112       43           50           111          39            212      198      211         189         Yes   6.5
  Yuan      2007   14        51        53           30           99           80            79       157      159         259         Yes   7.0
  Zhu       2006   110       226       172          102          268          173           446      570      472         614         Yes   8.0
  Chang     2014   30        114       50           57           199          135           174      214      313         469         Yes   7.5
  Zhang     2019   49        227       299          103          446          372           325      825      652         1190        Yes   8.0

HWE: Hardy--Weinberg equilibrium.

Meta-analysis results {#sec3-2}
---------------------

In the eligible investigations, the MAF of *MTHFR* rs1801133 C/T polymorphism was 0.475 in HCC patients (5,670/11,944) and was 0.466 in controls (5,721/12,288). In different race, the MAF of controls was not similar in controls. The MAFs were 0.352 (480/1,362) in mixed populations, 0.328 (214/652) in Caucasians, and that was 0.485 (5,075/10,462) in Asians.

The pooled-analysis findings were reported in four genetic models including 19 independent case--control studies. In recessive model (TT vs. CC/CT), the findings reached statistical significance (OR, 0.90; 95%CI, 0.82--0.98; *P* = 0.016, [Table 3](#T3){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). In other genetic models, we failed to obtain the significance (dominant model: OR, 0.92; 95%CI, 0.81--1.05; *P* = 0.209, homozygote model: OR, 0.88; 95%CI, 0.77--1.01; *P* = 0.078, and allele model: OR, 0.93; 95%CI, 0.85--1.01; *P* = 0.077, [Table 3](#T3){ref-type="table"}).

![Meta-analysis of the association between *MTHFR* rs1801133 polymorphism and HCC risk (recessive model, fixed-effects model)](bsr-40-bsr20194229-g2){#F2}

###### Results of the meta-analysis from different comparative genetic models

                               No. of studies   T vs. C                TT vs. CC     TT/CT vs. CC   TT vs. CT/CC                                                                                                                                                      
  ---------------------------- ---------------- ---------------------- ------------- -------------- -------------- ---------------------- ----------- ------- ------- ---------------------- ------------- ------- ------- ---------------------- ----------- ------- -------
  Total                        19               0.93(0.85--1.01)       0.077         48.7%          0.013          0.88(0.77--1.01)       0.078       25.8%   0.158   0.92(0.81--1.05)       0.209         47.3%   0.016   **0.90(0.82--0.98)**   **0.016**   11.9%   0.309
  Ethnicity                                                                                                                                                                                                                                                           
  Asians                       11               0.94(0.85--1.03)       0.182         63.4%          0.002          0.90(0.75--1.06)       0.210       50.1%   0.029   0.94(0.80--1.09)       0.380         59.3%   0.006   0.90(0.79--1.03)       0.133       44.4%   0.055
  Caucasians                   5                0.79(0.57--1.09)       0.153         0.0%           0.405          0.67(0.30--1.50)       0.331       0.0%    0.781   0.73(0.47--1.13)       0.155         42.2%   0.177   0.92(0.61--1.40)       0.693       0.0%    0.712
  Mixed                        3                0.94(0.76--1.17)       0.592         0.0%           0.549          0.86(0.52--1.41)       0.550       0.0%    0.721   0.94(0.70--1.27)       0.679         0.0%    0.494   0.89(0.56--1.42)       0.619       0.0%    0.874
  Sample sizes                                                                                                                                                                                                                                                        
  \<1000                       13               1.02(0.93--1.13)       0.631         25.8%          0.198          1.06(0.86--1.31)       0.559       0.0%    0.488   1.05(0.90--1.22)       0.537         31.3%   0.149   1.02(0.87--1.19)       0.857       0.0%    0.686
  ≥1000                        6                **0.88(0.80--0.96)**   **0.006**     52.6%          0.061          **0.80(0.70--0.92)**   **0.001**   29.1%   0.217   **0.84(0.73--0.97)**   **0.020**     48.8%   0.082   **0.85(0.76--0.94)**   **0.002**   35.3%   0.172
  Source of control                                                                                                                                                                                                                                                   
  P-B                          3                1.10(0.89--1.36)       0.374         53.7%          0.116          1.30(0.97--1.73)       0.080       39.9%   0.190   1.19(0.81--1.75)       0.385         65.0%   0.057   1.14(0.91--1.43)       0.248       0.0%    0.490
  H-B                          15               **0.88(0.83--0.93)**   **\<0.001**   22.9%          0.212          **0.81(0.71--0.92)**   **0.001**   0.0%    0.642   **0.84(0.77--0.93)**   **\<0.001**   23.2%   0.209   **0.85(0.77--0.94)**   **0.002**   0.0%    0.498
  NA                           1                0.96(0.73--1.26)       0.766         --             --             0.91(0.51--1.63)       0.743       --      --      0.91(0.56--1.48)       0.712         --      --      0.97(0.62--1.52)       0.887       --      --
  Control type                                                                                                                                                                                                                                                        
  Normal or healthy            10               0.95(0.84--1.08)       0.428         66.3%          0.002          0.92(0.74--1.16)       0.487       53.9%   0.021   0.95(0.79--1.15)       0.590         65.0%   0.002   0.94(0.79--1.11)       0.439       42.3%   0.076
  Hepatitis or virus related   7                **0.90(0.81--0.99)**   **0.028**     0.0%           0.533          0.82(0.67--1.00)       0.054       0.0%    0.905   0.90(0.56--1.06)       0.208         0.0%    0.463   **0.85(0.72--0.99)**   **0.035**   0.0%    0.695
  NA                           2                0.96(0.73--01.26)      0.766         --             --             0.91(0.51--1.63)       0.743       --      --      0.91(0.56--1.48)       0.712         --      --      0.93(0.64--1.35)       0.684       0.0%    0.729

P-B: population-based;

H-B: hospital-based

NA: not available

Subgroup analyses were carried out according to the following terms: ethnicity (Caucasians or Asians or mixed), sample sizes (\<1000 or ≥1000 subjects), control type \[normal/healthy subjects or hepatitis/virus related patients or not available (NA)\] and source of control \[hospital-based (HB) or population-based (PB) or NA\]. We pooled seven case--control studies (including 2,435 HCC cases and 1,642 hepatitis/virus related patients) and found an association between *MTHFR* rs1801133 polymorphism and decreased risk of HCC in hepatitis/virus related patients (recessive model: OR, 0.85; 95%CI, 0.72--0.99; *P* = 0.035, and allele model: OR, 0.90; 95%CI, 0.81--0.99; *P* = 0.028, [Table 3](#T3){ref-type="table"}). When we conducted a subgroup analysis by ethnicity, null association between *MTHFR* rs1801133 C\>T polymorphism and the risk of HCC was found.

Heterogeneity assessment {#sec3-3}
------------------------

In some genetic models, heterogeneity was significant ([Table 3](#T3){ref-type="table"}). Subgroup analyses indicated that extreme heterogeneity existed in Asian populations, larger sample size investigation, HB study and normal/healthy control subgroups. If we excluded these subgroups in our meta-analysis, the heterogeneity significantly decreased.

Bias evaluation {#sec3-4}
---------------

We used Begger's and Egger's tests to identify the bias of publication among the included investigations. The shape of Begger's test seemed symmetrical ([Figure 3](#F3){ref-type="fig"}). Egger's linear regression test also confirmed these evaluations.

![Begg's funnel plot of meta--analysis of the association between *MTHFR* rs1801133 polymorphism and HCC risk (recessive model, fixed-effects model)](bsr-40-bsr20194229-g3){#F3}

Sensitivity analyses {#sec3-5}
--------------------

By sequentially omitting an individual investigation, sensitivity analysis was carried out. This method is considered as a criterion for meta-analysis. The results indicated that the significance of the present study could not be altered by removing any case--control study ([Figure 4](#F4){ref-type="fig"}), suggesting that our findings were stable.

![Sensitivity analysis of the influence of *MTHFR* rs1801133 polymorphism to HCC risk (recessive model, fixed-effects model)](bsr-40-bsr20194229-g4){#F4}

Quality assessment {#sec3-6}
------------------

[Table 2](#T2){ref-type="table"} presents the results of the quality evaluation. Each eligible study had an acceptable quality (scores ≥ 6).

Discussion {#sec4}
==========

Accumulating investigations highlight that *MTHFR* rs1801133 polymorphism may be associated with the development of HCC. However, the findings of the previous case--control studies were conflicting, with several investigations suggesting a potential relationship, whereas others did not support the correlation. In this investigation, to explore whether the *MTHFR* rs1801133 polymorphism was implicated in the etiology of HCC, we carried out a pooled-analysis of 19 eligible studies, which recruited 6,102 HCC cases and 6,526 controls. This meta-analysis indicated that the *MTHFR* rs1801133 polymorphism was a protective factor for the development of HCC in the overall comparison. Compared with the previous study, this pooled-analysis first confirmed the association of *MTHFR* rs1801133 polymorphism with a decreased risk of HCC.

*MTHFR* rs1801133 polymorphism locates on 11796321 (NCBI Build 38) of Chromosome 1. Zhu and her/his colleagues first reported that *MTHFR* rs1801133 polymorphism might confer a risk to HCC \[[@B24]\]. In addition, Cui et al. also suggested that this polymorphism could increase the risk of HCC \[[@B20]\]. However, some case--control studies indicated that the rs1801133 polymorphism in *MTHFR* gene might decrease the susceptibility of HCC \[[@B21],[@B25]\]. And most studies reported that this SNP in *MTHFR* gene could not alter the risk of HCC. Thus, the association of *MTHFR* rs1801133 polymorphism with the susceptibility of HCC was more conflicting. Here, we performed a pooled-analysis of nineteen eligible studies involving 6,102 HCC cases and 6,526 controls to explore the correlation of rs1801133 with the etiology of HCC. The results indicated that this SNP in *MTHFR* gene could be a protective factor for the occurrence of HCC. Two meta-analyses suggested that rs1801133 was not associated with HCC development \[[@B43],[@B44]\]. Others pooled-analyses reported that *MTHFR* rs1801133 polymorphism was associated with an increased risk of HCC \[[@B45]\]. Compared with these early meta-analyses, our analysis included more large sample size studies \[[@B21],[@B25]\]. It is worth mentioning that these more recent case--control studies have recruited more participants and reported that rs1801133 polymorphism was a protective factor for the development of HCC. Compared with the most recent meta-analysis \[[@B23]\], the merit of our study was the larger sample size and the detailed subgroup analysis. Combined the eligible studies, we observed that rs1801133 decreased the susceptibility of HCC in the overall comparison. The quality score was evaluated in our study. Each eligible study had an acceptable quality (scores ≥6). This indicated that our findings were reliable. We also found an association between *MTHFR* rs1801133 polymorphism and decreased risk of HCC in hepatitis/virus related patients. Of late, in Asian population, some meta-analyses identified that *MTHFR* rs1801133 polymorphism decreased the risk of colorectal cancer \[[@B49],[@B50]\]. Some publications \[[@B51],[@B52]\] suggested that *MTHFR* rs1801133 C\>T polymorphism (Ala→Val) could promote the level of 5,10-methylene-THF for DNA synthesis, which might be protective to carcinogenesis. In the future, a functional study should be carried out to address how this Ala→Val substitution could decrease the risk of HCC.

Heterogeneity was identified in the overall comparison. In the present study, we conducted subgroup analyses to explore the major source among the eligible studies. Subgroup analysis suggested that major heterogeneity might be due to different populations, sample size, and characteristics of controls.

Some potential limitations should be addressed in this pooled-analysis. First, only published investigations were eligible in our study. Thus, the number of included case--control studies might be inadequate. Second, for lacking of sufficient data, only crude ORs and CIs were calculated. Third, the controls in some of the case--control studies were hepatitis or virus related patients. Fourth, a recent investigation contained some subgroups, we treated them as independent case--control studies. However, in this literature, the same HCC group was used in different stratified analysis. Finally, our study did not focus on the gene--gene and gene--environment interactions.

In summary, the present pooled-analysis highlights that *MTHFR* rs1801133 polymorphism is a protective factor for the occurrence of HCC, especially in hepatitis/virus related patients. The relationship of *MTHFR* rs1801133 polymorphism with HCC risk warrants a further determination.
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